As part of a regular review of safety reports for AstraZeneca's vaccine, Vaxzevria, the safety committee of the European Medicines Agency (EMA) is analysing data provided by the company on cases of Guillain-Barre syndrome (GBS), it said. RARE CONDITIONGBS is a rare neurological condition in which the body's immune system attacks the protective coating on nerve fibres. However, researchers have found the chances of developing GBS after vaccination are extremely small. On Friday, the EMA also said it was looking into reports of heart inflammation with Pfizer-BioNTech's vaccine, called Comirnaty, and Moderna's shot. Last week, the US Centers for Disease Control and Prevention said it had not found a link between heart inflammation and COVID-19 vaccines.

Source: bd News24 May 07, 2021 13:30 UTC